Products & ReviewLife Sciences

HD-X™ Automated Immunoassay Analyzer

QuanterixAvailable: Worldwide

HD-X Analyzer

0.0/5.0

|0 Reviews|Be the first to review this product

Request Pricing

Receive your quote directly from the manufacturer.

Ease of Use

After Sales Service

Value for Money

Be the first to leave a review

Description

Description
News & Articles

The Simoa HD-X Analyzer™ is the latest model of the fully automated Simoa bead-based immunoassay platform. Reengineered, the platform's ultrasensitivity and dependability empower researchers with 1000x greater sensitivity than traditional immunoassays.

Editorial ArticleDrug Discovery & Development

Simoa Technology aims to transform future Alzheimer's disease detection and treatment

Learn how biomarkers can be used to transform drug approval and patient management in neurodegenerative medicine

13 Nov 2024

Editorial ArticleLife Sciences

Ultrasensitive immunoassay technology drives blood-based biomarkers for Alzheimer's disease

Leveraging Quanterix’s Simoa platform, researchers lay the groundwork for pre-symptomatic Alzheimers diagnosis, guided treatment, and accelerated clinical drug trials

8 Feb 2024

Editorial ArticleLife Sciences

Detecting neurological biomarkers in blood: How ultra-sensitive immunoassays are making CNS biomarker detection less invasive

Learn how a blood test is being used to detect the Alzheimer’s disease biomarker, phosphorylated tau, in research and clinical diagnosis

2 Oct 2022

Product Overview

HD-X™ Automated Immunoassay Analyzer - Quanterix - Life Sciences

HD-X™ Automated Immunoassay Analyzer

0.0/5.0

Request Pricing

Links

Quanterix Manufacturer Website

Featured products

Request Quote for All Products

pTau-217 Assay
Quanterix
The Quanterix Simoa® ALZpath p-Tau 217 Assay provides an ultrasensitive, reliable solution for detecting phosphorylated Tau 217 (p-Tau 217) in blood. This critical biomarker is essential for Alzheimer’s research, offering insights into disease progression and helping differentiate Alzheimer’s from other forms of dementia.
(0)
NF-LIGHT™ Simoa Assay Kit
Quanterix
Neurofilament light (NF-L) is a 68 kDa cytoskeletal intermediate filament protein that is expressed in neurons. It associates with the 125 kDa Neurofilament medium(NF-M) and the 200 kDa Neurofilament heavy (NF-H) to form neurofilaments. They are major components of the neuronal cytoskeleton, and are believed to function primarily to provide structural support for the axon and to regulate axon diameter. Neurofilaments can be released in significant quantity following axonal damage or neuronal degeneration. NF-L has been shown to associate with traumatic brain injury, multiple sclerosis, frontotemporal dementia and other neurodegenerative diseases. The Simoa NF-light® assay is a digital immunoassay for the quantitative determination of NF-L in serum, plasma and CSF. The antibodies (Uman Diagnostics, Umeå Sweden) also cross react with murine, bovine, and macaque NF-L epitopes, and the assay can be used for research with these species. NF-light® is a registered trademark of Uman Diagnostics, Umeå Sweden.
(0)
SR-X™ Biomarker Detection System
Quanterix
Biomarker Detection System
(0)
SP-X Imaging and Analysis System™
Quanterix
Biomarker Measurement Detection
(0)
Simoa® Accelerator Laboratory
Quanterix
Protein Biomarker Testing and Custom Assay Development Services
(0)
Simoa Homebrew Kit
Quanterix
pTau181 Biomarker Assay
(0)
GFAP Simoa Assay Kit
Quanterix
Glial Fibrillary Acidic Protein (GFAP) is a class-III intermediate filament majorly expressed in astrocytic glial cells in the central nervous system. Astrocytes play a variety of key roles in supporting, guiding, nurturing, and signaling neuronal architecture and activity. Monomeric GFAP is about 55kD. It is capable of forming both homodimers and heterodimers; GFAP can polymerize with other type III proteins or with neurofilament protein (such as NF-L). GFAP is involved in many important CNS processes, including cell communication and the functioning of the blood brain barrier. GFAP, as a potential biomarker has been shown to associate with multiple diseases such as traumatic brain injury, stroke, brain tumors, etc. Decreases in GFAP expression have been reported in Down’s syndrome, schizophrenia, bipolar disorder, and depression.
(0)
NEUROLOGY 2-PLEX B (Nf-L, GFAP*)
Quanterix
The Simoa Human Neurology 2-Plex assay (N2PB) measures two important neurology biomarkers in both cerebrospinal fluid (CSF) and blood. The two targets are neurofilament light (Nf-L) and glial fibrillary acidic protein (GFAP™), which have been studied as indicators of traumatic brain injury (TBI) severity. N2PB has been developed as a 2-Plex version of the Neurology 4-Plex B assay (N4PB). *Banyan GFAP™ is a registered trademark of Banyan Biomarkers
(0)